Advertisement

Journal of Endocrinological Investigation

, Volume 41, Issue 4, pp 439–445 | Cite as

Does endogenous GLP-1 affect resting energy expenditure and fuel selection in overweight and obese adults?

  • E. Poggiogalle
  • L. M. Donini
  • C. Chiesa
  • L. Pacifico
  • A. Lenzi
  • S. Perna
  • M. Faliva
  • M. Naso
  • M. Rondanelli
Original Article
  • 134 Downloads

Abstract

Purpose

To investigate the association between fasting glucagon-like peptide 1 (GLP-1) levels and resting energy expenditure (REE), and respiratory quotient (RQ) in overweight and obese adults.

Method

Study participants were enrolled at the Dietetic and Metabolic Unit, University of Pavia, Italy. Inclusion criteria were age ≥ 25 and ≤ 45 years, and body mass index (BMI) ≥ 25 and ≤ 35 kg/m2. Diabetic subjects were excluded. Body composition was measured by dual-energy X-ray absorptiometry. REE was evaluated using indirect calorimetry, and RQ was calculated from respiratory gas exchanges. Fasting GLP-1, glucose, insulin and free fatty acid (FFA) levels, and 24-h norepinephrine urinary excretion were measured. Homeostasis model assessments of insulin resistance (HOMA-IR) and beta-cell function (HOMA-β) were calculated.

Results

Thirty-seven participants were included (age 43.4 ± 1.6 years; BMI 30.6 ± 0.5 kg/m2). REE was not associated with fasting GLP-1 levels (p = 0.98) after adjustment for age, sex, fat-free mass (FFM), and fat mass (FM). Similarly, no association was observed between RQ and GLP-1 levels (p = 0.95), after adjustment for age, sex, and body fat.

Conclusion

In adults subjects with increased adiposity fasting, GLP-1 levels do not seem to play a role in the regulation of energy metabolism and in fuel selection.

Keywords

Glucagon-like peptide 1 Resting energy expenditure Respiratory quotient Norepinephrine Obesity 

Notes

Author contributions

EP, LMD, and CC contributed equally to this work; MR and LMD designed the research; SP, MF, and MN performed the research; EP and LP analyzed the data; EP, LMD, CC, and AL wrote the paper. All authors participated in the critical review and in the final approval of the manuscript.

Compliance with ethical standards

Funding

No funding.

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Madsbad S (2014) The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications. Diabetes Obes Metab 16:9–21CrossRefPubMedGoogle Scholar
  2. 2.
    Katsurada K, Yada T (2016) Neural effects of gut- and brain-derived glucagon-like peptide-1 and its receptor agonist. J Diabetes Investig. 7:64–69CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Reimann F, Gribble FM (2016) Mechanisms underlying glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 secretion. J Diabetes Investig. 7:13–19CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Sun F, Chai S, Li L, Yu K, Yang Z, Wu S, Zhang Y, Ji L, Zhan S (2015) Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis. J Diabetes Res. 2015:157201CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Lindamood CA, Taylor JR (2015) Emerging new therapies for the treatment of type 2 diabetes mellitus: glucagon-like peptide-1 receptor agonists. Clin Ther 37:483–493CrossRefPubMedGoogle Scholar
  6. 6.
    Rondanelli M, Perna S, Astrone P, Grugnetti A, Solerte SB, Guido D (2016) Twenty-four-week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus. Patient Prefer Adherence. 10:407–413PubMedPubMedCentralGoogle Scholar
  7. 7.
    Hwa JJ, Ghibaudi L, Williams P, Witten MB, Tedesco R, Strader CD (1998) Differential effects of intracerebroventricular glucagon-like peptide-1 on feeding and energy expenditure regulation. Peptides 19:869–875CrossRefPubMedGoogle Scholar
  8. 8.
    Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, Hollenberg AN, Baggio L, Saper CB, Drucker DJ, Elmquist JK (2002) Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest. 110:43–52CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Yamamoto H, Kishi T, Lee CE, Choi BJ, Fang H, Hollenberg AN, Drucker DJ, Elmquist JK (2003) Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci 23:2939–2946PubMedGoogle Scholar
  10. 10.
    Nelson DL, Gehlert DR (2006) Central nervous system biogenic amine targets for control of appetite and energy expenditure. Endocrine 29:49–60CrossRefPubMedGoogle Scholar
  11. 11.
    Sprague JE, Yang X, Sommers J, Gilman TL, Mills EM (2007) Roles of norepinephrine, free Fatty acids, thyroid status, and skeletal muscle uncoupling protein 3 expression in sympathomimetic-induced thermogenesis. J Pharmacol Exp Ther 320:274–280CrossRefPubMedGoogle Scholar
  12. 12.
    Rondanelli M, Opizzi A, Perna S, Faliva M, Solerte SB, Fioravanti M, Klersy C, Cava E, Paolini M, Scavone L, Ceccarelli P, Castellaneta E, Savina C, Donini LM (2013) Acute effect on satiety, resting energy expenditure, respiratory quotient, glucagon-like peptide-1, free fatty acids, and glycerol following consumption of a combination of bioactive food ingredients in overweight subjects. J Am Coll Nutr 32:41–49CrossRefPubMedGoogle Scholar
  13. 13.
    Compher C, Frankenfield D, Keim N, Roth-Yousey L, Evidence Analysis Working Group (2006) Best practice methods to apply to measurement of resting metabolic rate in adults: a systematic review. J Am Diet Assoc 106:881–903CrossRefPubMedGoogle Scholar
  14. 14.
    Weir JB (1949) New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol 109:1–9CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefPubMedGoogle Scholar
  16. 16.
    Deurenberg P, Yap M, van Staveren WA (1998) Body mass index and percent body fat: a meta analysis among different ethnic groups. Int J Obes Relat Metab Disord 22:1164–1171CrossRefPubMedGoogle Scholar
  17. 17.
    Flint A, Raben A, Rehfeld JF, Holst JJ, Astrup A (2000) The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int J Obes Relat Metab Disord 24:288–298CrossRefPubMedGoogle Scholar
  18. 18.
    Flint A, Raben A, Ersbøll AK, Holst JJ, Astrup A (2001) The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 25:781–792CrossRefPubMedGoogle Scholar
  19. 19.
    Tan TM, Field BC, McCullough KA, Troke RC, Chambers ES, Salem V, Gonzalez Maffe J, Baynes KC, De Silva A, Viardot A, Alsafi A, Frost GS, Ghatei MA, Bloom SR (2013) Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes 62:1131–1138CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Bagger JI, Holst JJ, Hartmann B, Andersen B, Knop FK, Vilsbøll T (2015) Effect of oxyntomodulin, glucagon, GLP-1, and combined glucagon+ GLP-1 infusion on food intake, appetite, and resting energy expenditure. J Clin Endocrinol Metab 100:4541–4552CrossRefPubMedGoogle Scholar
  21. 21.
    Bradley DP, Kulstad R, Racine N, Shenker Y, Meredith M, Schoeller DA (2012) Alterations in energy balance following exenatide administration. Appl Physiol Nutr Metab 37:893–899CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH (2014) Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond). 38:784–793CrossRefGoogle Scholar
  23. 23.
    Pannacciulli N, Bunt JC, Koska J, Bogardus C, Krakoff J (2006) Higher fasting plasma concentrations of glucagon-like peptide 1 are associated with higher resting energy expenditure and fat oxidation rates in humans. Am J Clin Nutr 84:556–560CrossRefPubMedGoogle Scholar
  24. 24.
    Shalev A, Holst JJ, Keller U (1997) Effects of glucagon-like peptide 1 (7-36 amide) on whole-body protein metabolism in healthy man. Eur J Clin Invest 27:10–16CrossRefPubMedGoogle Scholar
  25. 25.
    Kuk JL, Ardern CI (2009) Are metabolically normal but obese individuals at lower risk for all-cause mortality? Diabetes Care. 32:2297–2299CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, Hüfner M, Schmiegel WH (2002) Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 87:1239–1246CrossRefPubMedGoogle Scholar
  27. 27.
    Macdonald IA (1995) Advances in our understanding of the role of the sympathetic nervous system in obesity. Int J Obes Relat Metab Disord 19:S2–S7PubMedGoogle Scholar
  28. 28.
    Piaggi P, Vinales KL, Basolo A, Santini F, Krakoff J (2017) Energy expenditure in the etiology of human obesity: spendthrift and thrifty metabolic phenotypes and energy-sensing mechanisms. J Endocrinol Invest. doi: 10.1007/s40618-017-0732-9
  29. 29.
    Tataranni PA, Young JB, Bogardus C, Ravussin E (1997) A low sympathoadrenal activity is associated with body weight gain and development of central adiposity in Pima Indian men. Obes Res 5:341–347CrossRefPubMedGoogle Scholar
  30. 30.
    Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Marks V (1996) Attenuated GLP-1 secretion in obesity: cause or consequence? Gut 38:916–919CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Ceccarini G, Maffei M, Vitti P, Santini F (2015) Fuel homeostasis and locomotor behavior: role of leptin and melanocortin pathways. J Endocrinol Invest 38:125–131CrossRefPubMedGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2017

Authors and Affiliations

  • E. Poggiogalle
    • 1
  • L. M. Donini
    • 1
  • C. Chiesa
    • 2
  • L. Pacifico
    • 3
  • A. Lenzi
    • 1
  • S. Perna
    • 4
  • M. Faliva
    • 4
  • M. Naso
    • 5
  • M. Rondanelli
    • 4
  1. 1.Medical Pathophysiology, Food Science and Endocrinology Section, Department of Experimental MedicineSapienza University of RomeRomeItaly
  2. 2.Institute of Translational PharmacologyNational Research CouncilRomeItaly
  3. 3.Department of Pediatrics and Childhood NeuropsychiatrySapienza University of RomeRomeItaly
  4. 4.Endocrinology and Nutrition Unit, Section of Human Nutrition, Department of Public Health, Experimental and Forensic MedicineUniversity of PaviaPaviaItaly
  5. 5.Department of Clinical SciencesUniversity of MilanMilanItaly

Personalised recommendations